Evercore ISI Lowers Baxter International (NYSE:BAX) Price Target to $23.00

Baxter International (NYSE:BAX) had its price target reduced by investment analysts at Evercore ISI from $24.00 to $23.00 in a report released on Monday,MarketScreener reports. Evercore ISI’s price objective would indicate a potential upside of 12.06% from the company’s current price.

A number of other research firms also recently weighed in on BAX. The Goldman Sachs Group cut their price target on shares of Baxter International from $25.00 to $22.00 and set a “neutral” rating on the stock in a research note on Friday, October 31st. Zacks Research raised Baxter International from a “strong sell” rating to a “hold” rating in a research report on Monday, December 1st. JPMorgan Chase & Co. reduced their target price on Baxter International from $25.00 to $19.00 in a report on Friday, October 31st. Argus lowered Baxter International from a “buy” rating to a “hold” rating in a research note on Friday, October 31st. Finally, Cowen restated a “hold” rating on shares of Baxter International in a report on Thursday, October 30th. Two analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $21.90.

Baxter International Stock Up 3.2%

BAX opened at $20.53 on Monday. The company has a fifty day moving average of $18.79 and a two-hundred day moving average of $22.95. The stock has a market capitalization of $10.55 billion, a price-to-earnings ratio of -31.10, a PEG ratio of 1.16 and a beta of 0.59. Baxter International has a fifty-two week low of $17.40 and a fifty-two week high of $37.74. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.18 and a current ratio of 1.84.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.09. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. The business had revenue of $2.84 billion during the quarter, compared to analysts’ expectations of $2.88 billion. During the same quarter in the previous year, the company earned $0.80 earnings per share. The company’s quarterly revenue was up 5.0% on a year-over-year basis. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. On average, research analysts expect that Baxter International will post 2.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Sciencast Management LP bought a new stake in shares of Baxter International in the first quarter worth about $356,000. Anchor Investment Management LLC grew its position in shares of Baxter International by 3.4% in the 1st quarter. Anchor Investment Management LLC now owns 21,164 shares of the medical instruments supplier’s stock valued at $724,000 after purchasing an additional 701 shares during the period. AG2R LA Mondiale Gestion D Actifs bought a new stake in Baxter International during the 1st quarter worth approximately $1,021,000. Park National Corp OH increased its stake in Baxter International by 2,691.4% during the 2nd quarter. Park National Corp OH now owns 219,512 shares of the medical instruments supplier’s stock worth $6,647,000 after purchasing an additional 211,648 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Baxter International by 40.1% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 2,831 shares of the medical instruments supplier’s stock worth $86,000 after buying an additional 810 shares during the period. Institutional investors and hedge funds own 90.19% of the company’s stock.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.